-+ 0.00%
-+ 0.00%
-+ 0.00%

ST Renfu (600079.SH) subsidiary interphenol oral tablet obtained drug registration certificate

Zhitongcaijing·09/11/2026 07:49:02
Listen to the news

Zhitong Finance App News, ST Renfu (600079.SH) issued an announcement. The company's holding subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., Ltd., recently received the “Drug Registration Certificate” approved and issued by the State Drug Administration. Recombinol tablets are used to treat acute spasmodic pain caused by digestive system and biliary tract dysfunction; acute spasmodic urethral, bladder, and renal colic; gynecological spasmodic pain. The approval of the drug indicates that the subsidiary is qualified to sell the product in the domestic market, which will further enrich the company's product line.